Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Salt Lake City, Utah 84107


This pilot study will evaluate home vision testing using a mobile medical application in participants with diabetic macular edema (DME) or neovascular age-related macula degeneration (nAMD) who receive intravitreal ranibizumab therapy. In the main, decentralized study, participants will be recruited via digital media, advocacy groups, or through their own ophthalmologist. The traditional substudy will evaluate the association between visual acuity and anatomical markers of disease status determined using clinical "gold standard" assessments (certified Early Treatment Diabetic Retinopathy Study [ETDRS] protocol visual acuity and macula optical coherence tomography [OCT]) and the results of home vision testing using the myVisionTrack^TM (mVT) application.


Inclusion Criteria: - DME or active nAMD in at least one eye - Current treatment with intravitreal ranibizumab therapy, with evaluations planned every 4 to 8 weeks - Access to an approved mobile device with a data plan or WiFi internet access Exclusion Criteria: - Any other eye condition causing eye disease that limits vision and cannot be corrected, other than DME or nAMD - Dementia or other neurologic or psychological limitation that would prevent the participant from performing regular self-testing of visual function



Primary Contact:

Study Director
Clinical Trials
Hoffmann-La Roche

Backup Contact:


Location Contact:

Salt Lake City, Utah 84107
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.